R/R NHL
5-Year Follow-up Analysis From ZUMA-5: a Phase 2 Trial of Axi-Cel in Patients With R/R Indolent Non-Hodgkin Lymphoma
Sattva Neelapu, et al
Data releases
Select scientific presentations
R/R LBCL
Real-Word Early Outcomes of Second-Line Axi-Cel Therapy in Patients with R/R LBCL
Dasom (Caroline) Lee, et al.
R/R MCL
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
Tom van Meerten, et al.
R/R LBCL
Predictors of Early Safety Outcomes with Axi-Cel in Patients with R/R LBCL
Christopher Sun Strouse, et al.
R/R LBCL
Real-world Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management among Patients Receiving Axi-cel for Relapsed or R/R LBCL in the US: a CIBMTR Report
Jiasheng Wang, et al.
R/R MM
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
Ciara Louise Freeman, et al
The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.
Learn more about the D-Domain
Select to view
To learn more from experts in cell therapy and access our medical education resources on demand, visit CellTherapyHub.com to find out more!
